Ecuador has approved the use of Chinese vaccine company CanSino Biologics Inc's (HKG: 6185) COVID-19 vaccine, Reuters news agency reported on Wednesday.
The President of Ecuador, Guillermo Lasso, had announced the purchase of six million doses of the CanSino shot, with the aim of vaccinating nine million people in the first 100 days of his government.
The Ecuador government is also negotiating the purchase of 18 million doses of Russia's Sputnik V COVID-19 vaccine and is asking pharmaceutical companies to speed up the delivery of doses they had previously agreed to provide.
According to Ecuador's health ministry, so far the country has vaccinated over a million people.
Ecuador expects to receive another 814,000 COVID-19 vaccines this week as part of deals already negotiated with laboratories, Reuters added.
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses